(VIANEWS) – Bergenbio’s stock surged 27.93% over 21 trading sessions from kr0.09 to kr0.12, marking four consecutive sessions of gains. Meanwhile, the Oslo Bors Benchmark Index_GI was up 1.32% at 1,290.31 after showing signs of weakness earlier. Bergenbio closed at just below its 52-week high of 13 which stood at 99.09% of that amount at one time.
About BERGENBIO
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on creating novel medicines to treat immune-evasive, drug-resistant and metastatic cancers as well as respiratory disorders. Bemcentinib, the company’s flagship drug, is an oral once-daily inhibitor of AXL receptor tyrosine kinase that is currently in Phase 1b/2a clinical trials for non-small cell lung cancer and Phase 2 trials for acute myeloid leukemia, COVID-19 glioblastoma 2L lung cancer melanoma pancreatic cancer mesothelioma. BerGenBio is currently testing an anti-AXL function-blocking monoclonal antibody known as Tilvestamab in Phase 1b trials for ovarian cancer patients and mipasetamab uzoptirine for solid tumor patients in Phase 1. They also have a collaboration agreement with Merck & Co for clinical trials; established in 2007 with headquarters in Bergen, Norway.
Yearly Analysis
Based on available data, Bergenbio’s stock is currently trading at kr0.12, significantly below its 52-week high of 13 and above its low of 0.08. This suggests a significant drop in value over the past year.
EBITDA, which measures earnings before interest, taxes, depreciation and amortization is currently at -2.91 for this company indicating it is operating at a loss, raising concern among investors.
Before investing, investors must carefully assess the current market conditions and financial performance of Bergenbio before making any definitive investment decisions. It may be worthwhile conducting further research or analysis to gain more insight into potential risks and rewards associated with investing in this stock.
Technical Analysis
BERGENBIO stock is experiencing a decrease in value, falling below both its 50-day and 200-day moving averages. Furthermore, the stock’s last reported volume (1866444668) represents 30.7% below its average volume of 35 749 800; suggesting lower trading activity.
BERGENBIO currently boasts an intraday variation average over the last week, month, and quarter of 3.51%, 1.01%, and 5.55% respectively; its highest average weekly volatility amplitude was recorded as 3.51% while monthly and quarterly average volatility reached 6.03% 6.03% and 5.55%, respectively.
The stochastic oscillator, an effective way of measuring overbought and oversold conditions, has classified BERGENBIO’s stock as oversold (=20) given its current value. Investors should keep an eye on these indicators to find the ideal time and price to purchase or sell shares of this company.
Equity Analysis
Bergenbio currently boasts a negative trailing twelve months return on equity of -179.58%, signalling to potential investors that it may not be effectively using its assets to generate profits for shareholders. Such results should raise red flags among potential investors as an inability to generate profits could indicate mismanagement and may signal that current management does not understand their assets to create profits effectively.
However, it’s important to keep in mind that a negative return on equity does not indicate poor overall company performance; rather, it could indicate investments made in research and development or long-term growth initiatives that did not generate immediate profits but may reap dividends later on.
Investors should also carefully consider other financial metrics, including revenue growth, operating margins and cash flow when assessing a company’s investment potential. A comprehensive financial analysis and consideration of multiple factors are advised before making any definitive investment decisions.
More news about BERGENBIO (BGBIO.OL).
